Navigation Links
Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Date:1/8/2008

BOSTON, Jan. 8 /PRNewswire/ -- Surface Logix today announced positive results in the Company's Phase 2a clinical trial of SLx-2101 in hypertension. The randomized, double-blind, placebo-controlled crossover Phase 2a study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well tolerated. The trial was designed to examine the safety, tolerability and effect on blood pressure in patients of repeat oral doses of SLx-2101 once daily for up to 14 days.

"These data confirm the promise of efficacy seen in earlier clinical trials, and we plan to initiate a Phase 2b study of SLx-2101 in hypertension in the third quarter of 2008," said Jim Mahoney, President and CEO of Surface Logix. "We believe that with our demonstrated 24-hour coverage from once daily dosing and excellent tolerability profile, we will be able to uniquely position SLx-2101 in several segments of the hypertension market."

SLx-2101 is an oral, potent, selective, fast-onset, long-acting PDE5 inhibitor. Other PDE5 inhibitors have traditionally been used to treat erectile dysfunction (ED). SLx-2101 was designed specifically to expand the therapeutic potential of PDE5 inhibition beyond ED into larger cardiovascular markets such as hypertension. SLx-2101 is uniquely positioned among the known PDE5 inhibitors to address cardiovascular disease because, compared to currently marketed PDE5 drugs, SLx-2101 preferentially distributes into cardiovascular tissue. With its large volume of distribution, SLx-2101 achieves sustained plasma levels and a long duration of action, without showing accumulation upon repeat dosing. This allows for daily or on demand dosing with a predictable response in a number of cardiovascular disorders that currently marketed PDE5 therapies cannot adequately address.

"To achieve efficacy in cardiovascular disease, your compound has to get into the right tissues," commented Dr. Pau
'/>"/>

SOURCE Surface Logix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surface Logix, Inc. to Present at the Piper Jaffray Health Care Conference
2. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
3. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
11. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
(Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
(Date:12/17/2014)... 2014 , The ... hub of information concerning the biopharmaceutical Group,s national and international ... addition to the recently launched institutional website that is receiving ... enriched by a new chapter in the fascinating story of ... detailed and panoramic hub on the world of clinical research, ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Company intends to release its second quarter 2011 financial results ... the U.S. financial markets.  The Company will also host a ... July 26, 2011 to discuss its financial results and provide ...
... BRUSSELS, June 30, 2011 UCB and Harvard University ... ceremony that took place in Boston last night in ... Belgium. (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) ... between industry and academia, with Harvard scientists continuing their ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings 2UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... ) that allege a metal-on-metal version of the ... move forward in state and federal courts, Bernstein ... in New Jersey’ Bergen County Superior Court on ... were permitted to begin deposition of plaintiffs on ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and retailer, ... The company has recently updated its official blog with ... season, Angeldress Blog has recommended some new ... prides itself in offering a huge selection of elegant ... company’s outfits are very carefully selected based on the ...
(Date:12/20/2014)... 2014 Developers of FCPX ... new plugin for Final Cut Pro X entitled TranSlice ... 5 allows users to create hand drawn text animations ... Austin, CEO of Pixel Film Studios. “TranSlice Volume 5 ... maintaining an easy to use interface.” , TranSlice Volume ...
(Date:12/19/2014)... Today, Balfleet.com , a leading dress company of ... promotion. All the old and new customers can get ... is well-known for its high quality trendy women’s dresses, ... and more. Its formal dresses are quality made and ... create an elegant look when paired with any accessory. ...
(Date:12/19/2014)... 2014 The Plantrician Project ... educational events, tools and resources for healthcare professionals ... , the world’s leading online cooking school, have ... being needs: Culinary Rx. As an online food ... Rx, scheduled for debut spring 2015, will be ...
Breaking Medicine News(10 mins):Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 2Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 3Health News:The Plantrician Project and the Rouxbe Cooking School Join Forces to Develop Culinary Rx – a Plant-Prescription Course 4
... the diet may help reduce the risk of developing kidney ... than 95,000 women who never had kidney stones, researchers documented ... study. Women who consumed the most calcium had a 27-percent ... consumed the least amount. The use of calcium supplements was ...
... new study simple strategies to improve lifestyle habits may ... high blood pressure reading .// ,Researchers investigated ... information booklet, encouraging lower sodium intake, and advice for ... effect as standard care. Nearly 300 patients without an ...
... cholesterol levels may be higher in colder months. So if ... // go get them checked now rather than wait till ... a study involving about 500 otherwise healthy men and women. ... basis over the year. Average total cholesterol was 222 milligrams/deciliter ...
... A new study shows Beer and liquor significantly increase the risk ... did not // appear to be a factor.Overall, the risk for ... grams of alcohol daily, the equivalent of four or five drinks. ... one drink, had a 30-percent increase in risk. ,When investigators ...
... Researchers from Japan say that the combination of chemotherapy ... cancer patients.// ,In the study of close ... higher in patients who received chemotherapy and the oral ... who received the combined therapy died within five years ...
... say , the leading cause of blindness for blacks ... degeneration // is the leading cause of blindness for ... of blindness for blacks. ,More than 50 percent ... of macular degeneration. In contrast, more than 60 percent ...
Cached Medicine News:
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
STABIBAG Hydrophilic Acrylic Lens....
BIGBAG Hydrophilic Acrylic Lens for high myopia....
One piece multifocal acrylic intraocular lens....
Medicine Products: